National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Secukinumab (Cosentyx®) for Psoriatic Arthritis

Cosentyx® alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

Rapid Review

Commenced Completed Outcome
02/12/2015 15/12/2015 Full Pharmacoeconomic Evaluation Not Recommended

The HSE has approved reimbursement following confidential price negotiations.